July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Intravitreal bevacizumab-loaded nanoparticles reduce choroidal neovascularization in laser-induced animal model.
Author Affiliations & Notes
  • Patricia Fernandez
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
  • Sergio Recalde
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
  • Maria Hernandez
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
  • Jaione Bezunartea
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
  • Juan Manuel Irache
    Department of Pharmacy and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Pamplona, Navarra, Spain
    IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
  • Ines Luis de Redin
    Department of Pharmacy and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Pamplona, Navarra, Spain
  • Idoia Belza
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
  • Elvira Rojas de Miguel
    Laboratory of Experimental Ophthalmology, University of Navarra, Pamplona, Navarra, Spain
  • Maite Moreno
    Laboratory of Experimental Ophthalmology, University of Navarra, Pamplona, Navarra, Spain
    IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
  • Elena Alonso
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
  • Alfredo Garcia-Layana
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
  • Footnotes
    Commercial Relationships   Patricia Fernandez, None; Sergio Recalde, None; Maria Hernandez, None; Jaione Bezunartea, None; Juan Irache, None; Ines Luis de Redin, None; Idoia Belza, None; Elvira Rojas de Miguel, None; Maite Moreno, None; Elena Alonso, None; Alfredo Garcia-Layana, None
  • Footnotes
    Support  Caja Navarra Foundation, Spanish Multicenter Group on AMD and the “Red Temática de Investigación Cooperativa en Salud,” RD07/0062, OFTARED RD12/0034 and RD16/0008
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1251. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Patricia Fernandez, Sergio Recalde, Maria Hernandez, Jaione Bezunartea, Juan Manuel Irache, Ines Luis de Redin, Idoia Belza, Elvira Rojas de Miguel, Maite Moreno, Elena Alonso, Alfredo Garcia-Layana; Intravitreal bevacizumab-loaded nanoparticles reduce choroidal neovascularization in laser-induced animal model.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1251.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The current study was designed to explore the efficacy of bevacizumab-loaded nanoparticles in a murine model of choroidal neovascularization (CNV).

Methods : Laser-induced CNV was performed in C57BL/6J mice and two days later mice received a single intravitreal injection (2 µl). Animals were divided into the following groups (n=6 per group): saline (S), bevacizumab (B), albumin (HSA) or HSA bevacizumab-loaded nanoparticles (HSA-BNP). Treatment outcome was studied after 7 and 14 days from laser induction by fluorescein angiography (CNV leakage) and immunofluorescence analysis of angiogenesis (CNV area, lectin). Statistical analysis was assessed by ANOVA followed by Bonferroni post-hoc or Kruskal Wallis and U-Mann Whitney (SPSS v 20.0). Differences p<0.05 were considered as significant.

Results : Analysis of CNV leakage showed a statistically significant reduction after intravitreal administration of HSA-BNP at 7 and 14 days after laser (p<0.01 and p<0.05, respectively) compared to HSA and S groups. B group only reduced leakage at day 14 compared to S (p<0.01). Furthermore, B and BNP groups showed a decrease in leakage at day 14 compared to day 7 (p<0.01). CNV area was only statistically reduced in HSA-BNP compared to S group (p<0.05).

Conclusions : Our findings suggest that HSA bevacizumab-loaded nanoparticles could be considered for inhibiting neovascularization processes. However, further studies are needed to confirm this and to evaluate molecules related to CNV. In summary, HSA bevacizumab-loaded nanoparticles might be an appropriate candidate for ocular delivery of bevacizumab and offer a new slow delivery system approach for inhibiting angiogenesis in retinal pathologies.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×